Our website uses cookies to improve your on-site experience. By using the website, cookies are being used as described in our Policy Document
Warning: To log in you will need to enable cookies and reload the page (Policy Document)
My ePortfolio Register   

AACR 2019 /
KEYNOTE 189: Targeting NSCLC patients with brain and liver metastases

29th Mar - 3rd Apr 2019

Please rate this video

Please complete at least one question.

  1. The information in this video was of interest to me Disagree Agree
  2. The information in this video is likely to improve my clinical practice or research Disagree Agree
  3. I would recommend this video to my colleagues Disagree Agree
Thanks for rating
There has been a problem, please refresh and try again.
Published: 15.04.19
Views: 1099

Dr Marina Garassino - National Tumor Institute, Milan, Italy

Dr Marina Garassino speaks to ecancer at the 2019 American Association for Cancer Research (AACR) meeting about the analysis of NSCLC patients with brain and liver metastases in the KEYNOTE 189 trial.

Dr Garassino states the frequency of brain and liver metastases in this disease type, along with the association with decreased prognosis in NSCLC patients.

She also describes the details of KEYNOTE 189 study, where investigators examined the effect of pembrolizumab plus pemetrexed and platinum-based chemotherapy as treatment for metastatic NSCLC.

Prof Garassino discusses the endpoints examined during the trial; in which the treatment regimen displayed an overall survival benefit and increased progression-free survival, just one year into the trial.

She also mentions that this treatment regimen has already been approved in several countries, with more countries expected to follow.

Previous conferences: highlights

Founding partners

European Cancer Organisation European Institute of Oncology

Founding Charities

Foundazione Umberto Veronesi Fondazione IEO Swiss Bridge

Published by

ecancer Global Foundation